Initiator Pharma A/S (SE:INIT)
:INIT
Top Page
Initiator Pharma A/S
(INIT)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr3.00
▼(-1.32% Downside)
Action:ReiteratedDate:02/21/26
The score is primarily constrained by weak financial performance (no revenue, higher losses, and ongoing cash burn), partially offset by a balance sheet that currently shows equity well above debt. Technicals are moderately supportive with price above key moving averages and positive MACD, while valuation support is limited due to negative earnings and no dividend.
Positive Factors
Balance sheet cushion
A materially larger equity base than debt provides a durable financial cushion, lowering immediate insolvency risk and giving the company runway to advance clinical programs. This improves negotiating leverage with partners and underpins short-to-medium-term program continuity.
Negative Factors
Pre-revenue profile
No product revenue means the company cannot self-fund operations or de-risk programs through sales. Long-term stability depends on successful clinical outcomes and external financing or partner deals, elevating execution and funding risk for the next 2–6 months and beyond.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet cushion
A materially larger equity base than debt provides a durable financial cushion, lowering immediate insolvency risk and giving the company runway to advance clinical programs. This improves negotiating leverage with partners and underpins short-to-medium-term program continuity.
Read all positive factors
Initiator Pharma A/S (INIT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr211.52M
Dividend YieldN/A
Average Volume (3M)133.41K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)N/A
Initiator Pharma A/S Business Overview & Revenue Model
Company Description
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectil...
How the Company Makes Money
Initiator Pharma A/S primarily makes money through external financing rather than recurring product sales because it is a clinical-stage company. Potential (and typically targeted) revenue sources for a company at this stage include upfront paymen...
Initiator Pharma A/S Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -14.83M | -11.07K | -23.41K | -38.42K | -21.63K |
| EBITDA | -18.20M | -14.50K | -27.03K | -41.73K | -23.06K |
| Net Income | -14.01M | -12.93K | -22.87K | -38.45M | -21.06M |
Balance Sheet | |||||
| Total Assets | 32.99M | 15.29M | 29.79M | 48.34M | 53.70M |
| Cash, Cash Equivalents and Short-Term Investments | 26.26M | 13.37M | 24.34M | 38.91M | 34.15M |
| Total Debt | 2.15M | 0.00 | 15.44M | 12.58M | 13.29M |
| Total Liabilities | 3.43M | 510.00K | 18.62M | 14.32M | 18.71M |
| Stockholders Equity | 29.56M | 14.78M | 11.16M | 34.02M | 34.99M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -12.08M | -17.65M | -32.70M | -34.10M |
| Operating Cash Flow | -18.19M | -12.08M | -17.65M | -32.70M | -34.10M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -17.00K | 0.00 |
| Financing Cash Flow | 31.36M | 1.11M | 2.87M | 37.48M | 54.94M |
Initiator Pharma A/S Peers Comparison
UnderperformOutperform
Sector (51)
SE:INIT
Initiator Pharma A/S
3.09
-2.55
-45.21%
SE:MVIR
Medivir AB
2.35
1.11
90.03%
DE:5IU
Isofol Medical AB
0.05
-0.09
-64.93%
DE:1XT
Xintela AB
0.01
-0.01
-47.62%
DE:99Z
Modus Therapeutics Holding AB
0.03
>-0.01
-11.76%
DE:BTPC
Active Biotech AB
0.01
<0.01
20.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.